Skip to content

Human and Microbial Determinants of the Onset of IBD Flares

Microbial and Human Determinants of the Onset of IBD Flares

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06967311
Enrollment
100
Registered
2025-05-13
Start date
2025-01-31
Completion date
2030-02-28
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IBD (Inflammatory Bowel Disease)

Keywords

observational, IBD, microbiome

Brief summary

This study will collect longitudinal biological samples and survey data to identify the triggers of IBD flares.

Detailed description

This is a longitudinal observational study whose goals are to identify: Microbial and human molecular triggers of IBD relapses, Microbial and human molecular pathways strongly associated with flares that could be targeted with nutrition with a therapeutic potential, Biomarkers of IBD for Dx purposes, Identify microbial functions associated with release of BH4.

Interventions

None listed

Sponsors

Universidade Federal de Santa Catarina
CollaboratorOTHER
Viome
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient at Universidade Federal de Santa Catarina (UFSC) Hospital, under care of Dr. Vivian Menegassi

Exclusion criteria

* Cancer Diagnosis/Treatment * Under 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Stool microbial KEGG orthologs (KOs) associated with IBDFor 12 months from enrollmentMetatranscriptomic tests will be used to quantify microbial KOs in stool samples. At the end of the study, we will use machine learning to identify KOs whose expression is associated with IBD.

Countries

Brazil

Contacts

Primary ContactRaquel Clinical Research Coordinator
studies@viome.com425-368-5248
Backup ContactMomo Vuyisich Chief Science Officer, PhD
studies@viome.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026